Association of tumour and stroma PD-1, PD-L1, CD3, CD4 and CD8 expression with DCB and OS to nivolumab treatment in NSCLC patients pre-treated with chemotherapy.
Aged
Antineoplastic Agents, Immunological
/ administration & dosage
B7-H1 Antigen
/ metabolism
CD3 Complex
/ metabolism
CD4 Antigens
/ metabolism
CD8 Antigens
/ metabolism
Carcinoma, Non-Small-Cell Lung
/ drug therapy
Female
Gene Expression Regulation, Neoplastic
/ drug effects
Humans
Lung Neoplasms
/ drug therapy
Male
Middle Aged
Nivolumab
/ administration & dosage
Programmed Cell Death 1 Receptor
/ metabolism
Retrospective Studies
Survival Analysis
Treatment Outcome
Tumor Microenvironment
/ drug effects
Journal
British journal of cancer
ISSN: 1532-1827
Titre abrégé: Br J Cancer
Pays: England
ID NLM: 0370635
Informations de publication
Date de publication:
08 2020
08 2020
Historique:
received:
03
09
2019
accepted:
22
04
2020
revised:
30
03
2020
pubmed:
21
5
2020
medline:
26
2
2021
entrez:
21
5
2020
Statut:
ppublish
Résumé
Immune checkpoint inhibitors are most beneficial in patients with high tumour PD-L1 expression. However, the use of PD-L1 expression is not straightforward. We investigated PD-L1 expression and immune cell (IC) infiltrates in non-small-cell lung cancer (NSCLC) patients treated with nivolumab. Tumour tissue specimens of 139 NSCLC patients were scored for tumour/stromal PD-L1 and various IC expression markers, and associated with durable clinical benefit (DCB) and overall survival (OS). Median OS was higher for patients with high stromal infiltration of CD8 Stromal infiltration of ICs can predict response to PD-1-directed immunotherapy in NSCLC patients. Interestingly, we found differences in the predictive value of IC markers between the ACT and BCT biopsies, suggesting that chemotherapy might influence the immune microenvironment.
Sections du résumé
BACKGROUND
Immune checkpoint inhibitors are most beneficial in patients with high tumour PD-L1 expression. However, the use of PD-L1 expression is not straightforward. We investigated PD-L1 expression and immune cell (IC) infiltrates in non-small-cell lung cancer (NSCLC) patients treated with nivolumab.
METHODS
Tumour tissue specimens of 139 NSCLC patients were scored for tumour/stromal PD-L1 and various IC expression markers, and associated with durable clinical benefit (DCB) and overall survival (OS).
RESULTS
Median OS was higher for patients with high stromal infiltration of CD8
CONCLUSIONS
Stromal infiltration of ICs can predict response to PD-1-directed immunotherapy in NSCLC patients. Interestingly, we found differences in the predictive value of IC markers between the ACT and BCT biopsies, suggesting that chemotherapy might influence the immune microenvironment.
Identifiants
pubmed: 32433601
doi: 10.1038/s41416-020-0888-5
pii: 10.1038/s41416-020-0888-5
pmc: PMC7403301
doi:
Substances chimiques
Antineoplastic Agents, Immunological
0
B7-H1 Antigen
0
CD274 protein, human
0
CD3 Complex
0
CD4 Antigens
0
CD8 Antigens
0
PDCD1 protein, human
0
Programmed Cell Death 1 Receptor
0
Nivolumab
31YO63LBSN
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
392-402Références
Liontos, M., Anastasiou, I., Bamias, A. & Dimopoulos, M. A. DNA damage, tumor mutational load and their impact on immune responses against cancer. Ann. Transl. Med. 4, 264 (2016).
pubmed: 27563651
pmcid: 4971372
Keir, M. E., Butte, M. J., Freeman, G. J. & Sharpe, A. H. PD-1 and its ligands in tolerance and immunity. Annu. Rev. Immunol. 26, 677–704 (2008).
pubmed: 18173375
Pardoll, D. M. The blockade of immune checkpoints in cancer immunotherapy. Nat. Rev. Cancer 12, 252–264 (2012).
pubmed: 22437870
pmcid: 4856023
Brahmer, J., Reckamp, K. L., Baas, P., Crino, L., Eberhardt, W. E., Poddubskaya, E. et al. Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer. N. Engl. J. Med. 373, 123–135 (2015).
pubmed: 26028407
pmcid: 4681400
Borghaei, H., Paz-Ares, L., Horn, L., Spigel, D. R., Steins, M., Ready, N. E. et al. Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer. N. Engl. J. Med. 373, 1627–1639 (2015).
pubmed: 26412456
pmcid: 5705936
Gettinger, S. N., Horn, L., Gandhi, L., Spigel, D. R., Antonia, S. J., Rizvi, N. A. et al. Overall survival and long-term safety of nivolumab (anti-programmed death 1 antibody, BMS-936558, ONO-4538) in patients with previously treated advanced non-small-cell lung cancer. J. Clin. Oncol. 33, 2004–2012 (2015).
pubmed: 25897158
pmcid: 4672027
Gandara, D. R., Paul, S. M., Kowanetz, M., Schleifman, E., Zou, W., Li, Y. et al. Blood-based tumor mutational burden as a predictor of clinical benefit in non-small-cell lung cancer patients treated with atezolizumab. Nat. Med. 24, 1441–1448 (2018).
pubmed: 30082870
Hellmann, M. D., Ciuleanu, T. E., Pluzanski, A., Lee, J. S., Otterson, G. A., Audigier-Valette, C. et al. Nivolumab plus ipilimumab in lung cancer with a high tumor mutational burden. N. Engl. J. Med. 378, 2093–2104 (2018).
pubmed: 29658845
pmcid: 7193684
Garon, E. B., Rizvi, N. A., Hui, R., Leighl, N., Balmanoukian, A. S., Eder, J. P. et al. Pembrolizumab for the treatment of non-small-cell lung cancer. N. Engl. J. Med. 372, 2018–2028 (2015).
pubmed: 25891174
Reck, M., Rodriguez-Abreu, D., Robinson, A. G., Hui, R., Csoszi, T., Fulop, A. et al. Pembrolizumab versus chemotherapy for PD-L1-positive non-small-cell lung cancer. N. Engl. J. Med. 375, 1823–1833 (2016).
pubmed: 27718847
Hirsch, F. R., McElhinny, A., Stanforth, D., Ranger-Moore, J., Jansson, M., Kulangara, K. et al. PD-L1 immunohistochemistry assays for lung cancer: results from phase 1 of the blueprint PD-L1 IHC assay comparison project. J. Thorac. Oncol. 12, 208–222 (2017).
pubmed: 27913228
Teng, M. W., Ngiow, S. F., Ribas, A. & Smyth, M. J. Classifying cancers based on t-cell infiltration and PD-L1. Cancer Res. 75, 2139–2145 (2015).
pubmed: 25977340
pmcid: 4452411
Taube, J. M., Klein, A., Brahmer, J. R., Xu, H., Pan, X., Kim, J. H. et al. Association of PD-1, PD-1 ligands, and other features of the tumor immune microenvironment with response to anti-PD-1 therapy. Clin. Cancer Res. 20, 5064–5074 (2014).
pubmed: 24714771
pmcid: 4185001
Tumeh, P. C., Harview, C. L., Yearley, J. H., Shintaku, I. P., Taylor, E. J., Robert, L. et al. PD-1 blockade induces responses by inhibiting adaptive immune resistance. Nature 515, 568–571 (2014).
pubmed: 25428505
pmcid: 4246418
Herbst, R. S., Soria, J. C., Kowanetz, M., Fine, G. D., Hamid, O., Gordon, M. S. et al. Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients. Nature 515, 563–567 (2014).
pubmed: 25428504
pmcid: 4836193
Bubendorf, L., Buttner, R., Al-Dayel, F., Dietel, M., Elmberger, G., Kerr, K. et al. Testing for ROS1 in non-small cell lung cancer: a review with recommendations. Virchows Arch. 469, 489–503 (2016).
pubmed: 27535289
pmcid: 5082594
Thunnissen, E., Allen, T. C., Adam, J., Aisner, D. L., Beasley, M. B., Borczuk, A. C. et al. Immunohistochemistry of pulmonary biomarkers: a perspective from members of the pulmonary pathology society. Arch. Pathol. Lab. Med. 142, 408–419 (2018).
pubmed: 28686497
Galon, J., Costes, A., Sanchez-Cabo, F., Kirilovsky, A., Mlecnik, B., Lagorce-Pages, C. et al. Type, density, and location of immune cells within human colorectal tumors predict clinical outcome. Science 313, 1960–1964 (2006).
pubmed: 17008531
Donnem, T., Hald, S. M., Paulsen, E. E., Richardsen, E., Al-Saad, S., Kilvaer, T. K. et al. Stromal CD8+ T-cell density-a promising supplement to TNM staging in non-small cell lung cancer. Clin. Cancer Res. 21, 2635–2643 (2015).
pubmed: 25680376
Paulsen, E. E., Kilvaer, T. K., Khanehkenari, M. R., Al-Saad, S., Hald, S. M., Andersen, S. et al. Assessing PDL-1 and PD-1 in Non-small cell lung cancer: a novel immunoscore approach. Clin. Lung Cancer 18, 220–233 (2017).
pubmed: 27816392
Eisenhauer, E. A., Therasse, P., Bogaerts, J., Schwartz, L. H., Sargent, D., Ford, R. et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur. J. Cancer 45, 228–247 (2009).
pubmed: 19097774
Mazzaschi, G., Facchinetti, F., Missale, G., Canetti, D., Madeddu, D., Zecca, A. et al. The circulating pool of functionally competent NK and CD8+ cells predicts the outcome of anti-PD1 treatment in advanced NSCLC. Lung Cancer 127, 153–163 (2019).
pubmed: 30642544
Fumet, J. D., Richard, C., Ledys, F., Klopfenstein, Q., Joubert, P., Routy, B. et al. Prognostic and predictive role of CD8 and PD-L1 determination in lung tumor tissue of patients under anti-PD-1 therapy. Br. J. Cancer 119, 950–960 (2018).
pubmed: 30318514
pmcid: 6203820
Daud, A. I., Loo, K., Pauli, M. L., Sanchez-Rodriguez, R., Sandoval, P. M., Taravati, K. et al. Tumor immune profiling predicts response to anti-PD-1 therapy in human melanoma. J. Clin. Invest. 126, 3447–3452 (2016).
pubmed: 27525433
pmcid: 5004965
Soo, R. A., Chen, Z., Yan Teng, R. S., Tan, H. L., Iacopetta, B., Tai, B. C. et al. Prognostic significance of immune cells in non-small cell lung cancer: meta-analysis. Oncotarget 9, 24801–24820 (2018).
pubmed: 29872507
pmcid: 5973851
de Biasi, A. R., Villena-Vargas, J. & Adusumilli, P. S. Cisplatin-induced antitumor immunomodulation: a review of preclinical and clinical evidence. Clin. Cancer Res. 20, 5384–5391 (2014).
pubmed: 25204552
pmcid: 4216745
Parra, E. R., Villalobos, P., Behrens, C., Jiang, M., Pataer, A., Swisher, S. G. et al. Effect of neoadjuvant chemotherapy on the immune microenvironment in non-small cell lung carcinomas as determined by multiplex immunofluorescence and image analysis approaches. J. Immunother. Cancer 6, 48 (2018).
pubmed: 29871672
pmcid: 5989476
Deng, L., Liang, H., Burnette, B., Beckett, M., Darga, T., Weichselbaum, R. R. et al. Irradiation and anti-PD-L1 treatment synergistically promote antitumor immunity in mice. J. Clin. Invest. 124, 687–695 (2014).
pubmed: 24382348
pmcid: 3904601
Zhang, P., Su, D. M., Liang, M. & Fu, J. Chemopreventive agents induce programmed death-1-ligand 1 (PD-L1) surface expression in breast cancer cells and promote PD-L1-mediated T cell apoptosis. Mol. Immunol. 45, 1470–1476 (2008).
pubmed: 17920123
Omori, S., Kenmotsu, H., Abe, M., Watanabe, R., Sugino, T., Kobayashi, H. et al. Changes in programmed death ligand 1 expression in non-small cell lung cancer patients who received anticancer treatments. Int J. Clin. Oncol. 23, 1052–1059 (2018).
pubmed: 29948239
Herbst, R. S., Baas, P., Perez-Gracia, J. L., Felip, E., Kim, D. W., Han, J. Y. et al. Use of archival versus newly collected tumor samples for assessing PD-L1 expression and overall survival: an updated analysis of KEYNOTE-010 trial. Ann. Oncol. 30, 281–289 (2019).
pubmed: 30657853
pmcid: 6931268
Lin, H., Wei, S., Hurt, E. M., Green, M. D., Zhao, L., Vatan, L. et al. Host expression of PD-L1 determines efficacy of PD-L1 pathway blockade-mediated tumor regression. J. Clin. Invest. 128, 805–815 (2018).
pubmed: 29337305
pmcid: 5785251
Tang, H., Liang, Y., Anders, R. A., Taube, J. M., Qiu, X., Mulgaonkar, A. et al. PD-L1 on host cells is essential for PD-L1 blockade-mediated tumor regression. J. Clin. Invest. 128, 580–588 (2018).
pubmed: 29337303
pmcid: 5785245
Carbone, D. P., Reck, M., Paz-Ares, L., Creelan, B., Horn, L., Steins, M. et al. First-line nivolumab in stage iv or recurrent non-small-cell lung cancer. N. Engl. J. Med. 376, 2415–2426 (2017).
pubmed: 28636851
pmcid: 6487310
Kowanetz, M., Zou, W., Gettinger, S. N., Koeppen, H., Kockx, M., Schmid, P. et al. Differential regulation of PD-L1 expression by immune and tumor cells in NSCLC and the response to treatment with atezolizumab (anti-PD-L1). Proc. Natl Acad. Sci. USA 115, 10119–10126 (2018).
Casadevall, D., Clave, S., Taus, A., Hardy-Werbin, M., Rocha, P., Lorenzo, M. et al. Heterogeneity of tumor and immune cell PD-L1 expression and lymphocyte counts in surgical NSCLC samples. Clin. Lung Cancer 18, 682–691 (2017).
pubmed: 28549836
Gniadek, T. J., Li, Q. K., Tully, E., Chatterjee, S., Nimmagadda, S. & Gabrielson, E. Heterogeneous expression of PD-L1 in pulmonary squamous cell carcinoma and adenocarcinoma: implications for assessment by small biopsy. Mod. Pathol. 30, 530–538 (2017).
pubmed: 28059094
Ilie, M., Long-Mira, E., Bence, C., Butori, C., Lassalle, S., Bouhlel, L. et al. Comparative study of the PD-L1 status between surgically resected specimens and matched biopsies of NSCLC patients reveal major discordances: a potential issue for anti-PD-L1 therapeutic strategies. Ann. Oncol. 27, 147–153 (2016).
pubmed: 26483045
Bigras, G., Mairs, S., Swanson, P. E., Morel, D., Lai, R. & Izevbaye, I. Small biopsies misclassify up to 35% of PD-L1 assessments in advanced lung non-small cell lung carcinomas. Appl. Immunohistochem. Mol. Morphol. 26, 701–708 (2018).
pubmed: 30095468
Freidin, M. B., Bhudia, N., Lim, E., Nicholson, A. G., Cookson, W. O. & Moffatt, M. F. Impact of collection and storage of lung tumor tissue on whole genome expression profiling. J. Mol. Diagn. 14, 140–148 (2012).
pubmed: 22240448
pmcid: 3547171
van Dongen, G. A., Poot, A. J. & Vugts, D. J. PET imaging with radiolabeled antibodies and tyrosine kinase inhibitors: immuno-PET and TKI-PET. Tumour Biol. 33, 607–615 (2012).
pubmed: 22270450
pmcid: 3342498
Pelekanou, V., Barlow, W. E., Nahleh, Z. A., Wasserman, B., Lo, Y. C., von Wahlde, M. K. et al. Tumor-infiltrating lymphocytes and PD-L1 expression in pre- and posttreatment breast cancers in the SWOG S0800 phase II neoadjuvant chemotherapy trial. Mol. Cancer Ther. 17, 1324–1331 (2018).
pubmed: 29588392
pmcid: 6548451
Yang, J. H., Kim, H., Roh, S. Y., Lee, M. A., Park, J. M., Lee, H. H. et al. Discordancy and changes in the pattern of programmed death ligand 1 expression before and after platinum-based chemotherapy in metastatic gastric cancer. Gastric Cancer 22, 147–154 (2018).
pubmed: 29860599